We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Destiny Pharma Plc | LSE:DEST | London | Ordinary Share | GB00BDHSP575 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.50 | 2.94% | 17.50 | 17.00 | 18.00 | 17.50 | 17.50 | 17.50 | 599 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -6.5M | -0.0683 | -2.49 | 16.2M |
Date | Subject | Author | Discuss |
---|---|---|---|
21/1/2021 20:28 | Anyone tune in to the presentation? | mikeh30 | |
21/1/2021 14:40 | that video now on ggp share board , a good example for other shares | bunz3 | |
20/1/2021 13:15 | Biden and the next chapter for global stock markets (podcast with discussion on Destiny Pharma). | sev22 | |
20/1/2021 12:21 | I am in no way a chartist but is that a cup and handle formation ? | okidokicoki | |
19/1/2021 18:37 | Would like to see a partnership between DP and Oxford as the latter have the brand and the capital backing and together I think they could be a great partnership.... | supracat | |
19/1/2021 17:58 | I see the Oxford Institute AMR news as being very positive for DEST. This will clearly raise awareness of the demand for AMR drugs and the opportunity therein. Fact is DEST must be 5 - 10 years ahead of the Oxford Inst, bearing in mind they are just setting up and DEST at end of P2B. Good to see step up in PR with these 2 events and more. I presume timed to closely coincide with the P2B results. | kipper1960 | |
19/1/2021 16:34 | Looks like there are two opportunities to listen to te investment case in the next couple of weeks Destiny are also presenting at the Proactive one2one investors forum this Thursday (21st January) Click here to register | timbo003 | |
19/1/2021 13:21 | Shares Investor Evening - Webinar. | sev22 | |
19/1/2021 11:21 | Also added | malcolmmm | |
19/1/2021 10:13 | Lengthy segment too for sky news. Huge huge focus on AMR | mikeh30 | |
19/1/2021 10:11 | Great news this as brings the sector into the radar and DP should benefit off the back of this as being at the forefront. | supracat | |
19/1/2021 09:34 | Added at 112 | prince7652 | |
19/1/2021 09:34 | Wh1spa Very good article if only there was something in trials that could solve the problem :-) | okidokicoki | |
19/1/2021 09:23 | It's doubled in a short time. Profits taken yesterday now the inexperienced booking losses. Yawn. Wake me up at £3 | mikeh30 | |
19/1/2021 09:20 | MMs trying to shake out some sellers past couple of days with these share price movements and spreads. | supracat | |
18/1/2021 11:51 | Just been down the back of the sofa and bought a few more:-) | okidokicoki | |
18/1/2021 11:24 | It's not just that it's preventative that I like (an ounce of prevention) it's also that the XF-73 platform will continue to produce further gels and sprays and that each of these will be used by doctors and surgeons as consumables. If the trials are successful and we get the right commercial partner (probably already well underway) the goal is to get into the lucrative US market and for our preventative medicines to be used routinely to prevent MRSA and COVID. Looks very positive here for the next few years. | gb904150 | |
18/1/2021 11:07 | VoluMe is stil quite low despite the share price rises. | supracat | |
18/1/2021 10:34 | Must be starting to get on people's radar with the rises we have had in the last few weeks, its almost doubled in price in the last few weeks . Its a beautiful thing :-) | okidokicoki | |
18/1/2021 08:53 | I totally agree. This could be very big. | idriveajag | |
16/1/2021 07:53 | Ty Carlisle. Hope you are also holding a good number too. | supracat | |
15/1/2021 15:59 | Another good day and another decent uplift off the back of this momentum. Next challenge line of resistance is still around 190p so will be interesting to see what happens over the coming days and weeks. I firmly believe the recent CBO role is ahead of positive results in Q1 from the Xf73 trials. Assuming good trial data coming through I'd like to see a clear plan and who DP will partner with to get through Phase 3, and critically what cash up front has been agreed. | supracat |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions